Compare Mesoblast Limited (MESO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Oatly Group AB - ADR — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Oatly Group AB - ADR trades at $9.46 (market cap $308.50M). The key difference: Mesoblast Limited is far larger — about 7× Oatly Group AB - ADR's market cap, and Mesoblast Limited is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| MESO | OTLY | |
|---|---|---|
Market Cap | $2.17B | $308.50M |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $18.54 |
52-Week Low | $12.88 | $8.03 |
Enterprise Value | $2.17B | $806.12M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
OTLY trades at $9.81, down 2.29% on the day, with a bullish technical signal from moving averages. Revenue grew to $862.46M in 2025, but net losses persist at -$152.77M. Cash burn remains a concern with negative operating cash flow of -$23.72M. The company announced Q2 2026 results for July 22, 2026, and continues brand partnerships like the Nespresso iced coffee collaboration.
Outlook is mixed: strong brand and revenue growth offer potential, but profitability challenges and high debt-to-asset ratio of 66.53% pose significant risks. Analyst consensus is divided with 44% buy ratings, yet cash runway constraints highlighted by Seeking Alpha on 2026-05-14 require careful monitoring for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
